620 related articles for article (PubMed ID: 28298600)
1. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
J Virol; 2017 May; 91(10):. PubMed ID: 28298600
[TBL] [Abstract][Full Text] [Related]
2. Dengue Protease Substrate Recognition: Binding of the Prime Side.
Lin KH; Nalivaika EA; Prachanronarong KL; Yilmaz NK; Schiffer CA
ACS Infect Dis; 2016 Oct; 2(10):734-743. PubMed ID: 27657335
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.
Takagi Y; Matsui K; Nobori H; Maeda H; Sato A; Kurosu T; Orba Y; Sawa H; Hattori K; Higashino K; Numata Y; Yoshida Y
Bioorg Med Chem Lett; 2017 Aug; 27(15):3586-3590. PubMed ID: 28539222
[TBL] [Abstract][Full Text] [Related]
4. Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease.
Velmurugan D; Mythily U; Rao K
Protein Pept Lett; 2014; 21(8):815-27. PubMed ID: 23855663
[TBL] [Abstract][Full Text] [Related]
5. Ligand-bound structures of the dengue virus protease reveal the active conformation.
Noble CG; Seh CC; Chao AT; Shi PY
J Virol; 2012 Jan; 86(1):438-46. PubMed ID: 22031935
[TBL] [Abstract][Full Text] [Related]
6. In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.
Dwivedi VD; Tripathi IP; Mishra SK
J Vector Borne Dis; 2016; 53(2):156-61. PubMed ID: 27353586
[TBL] [Abstract][Full Text] [Related]
7. Exploiting the unique features of Zika and Dengue proteases for inhibitor design.
Majerová T; Novotný P; Krýsová E; Konvalinka J
Biochimie; 2019 Nov; 166():132-141. PubMed ID: 31077760
[TBL] [Abstract][Full Text] [Related]
8. Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors.
Zhou GC; Weng Z; Shao X; Liu F; Nie X; Liu J; Wang D; Wang C; Guo K
Bioorg Med Chem Lett; 2013 Dec; 23(24):6549-54. PubMed ID: 24268549
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR and molecular docking studies of peptide-hybrids as dengue virus NS2B/NS3 protease inhibitors.
Jitonnom J; Meelua W; Tue-Nguen P; Saparpakorn P; Hannongbua S; Chotpatiwetchkul W
Chem Biol Interact; 2024 Jun; 396():111040. PubMed ID: 38735453
[TBL] [Abstract][Full Text] [Related]
10. Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
Lai H; Teramoto T; Padmanabhan R
Methods Mol Biol; 2014; 1138():345-60. PubMed ID: 24696347
[TBL] [Abstract][Full Text] [Related]
11. A quinoline compound inhibits the replication of dengue virus serotypes 1-4 in Vero cells.
Beesetti H; Tyagi P; Medapi B; Krishna VS; Sriram D; Khanna N; Swaminathan S
Antivir Ther; 2018; 23(5):385-394. PubMed ID: 29583121
[TBL] [Abstract][Full Text] [Related]
12. Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses.
Rut W; Groborz K; Zhang L; Modrzycka S; Poreba M; Hilgenfeld R; Drag M
Antiviral Res; 2020 Mar; 175():104731. PubMed ID: 32014497
[TBL] [Abstract][Full Text] [Related]
13. The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection.
Starvaggi J; Previti S; Zappalà M; Ettari R
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673962
[TBL] [Abstract][Full Text] [Related]
14. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication.
Kouretova J; Hammamy MZ; Epp A; Hardes K; Kallis S; Zhang L; Hilgenfeld R; Bartenschlager R; Steinmetzer T
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):712-721. PubMed ID: 28385094
[TBL] [Abstract][Full Text] [Related]
15. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.
Tomlinson SM; Watowich SJ
Antiviral Res; 2011 Feb; 89(2):127-35. PubMed ID: 21185332
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease.
Bharadwaj S; Lee KE; Dwivedi VD; Yadava U; Panwar A; Lucas SJ; Pandey A; Kang SG
Sci Rep; 2019 Dec; 9(1):19059. PubMed ID: 31836806
[TBL] [Abstract][Full Text] [Related]
17. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors.
Tomlinson SM; Watowich SJ
Antiviral Res; 2012 Feb; 93(2):245-252. PubMed ID: 22193283
[TBL] [Abstract][Full Text] [Related]
18. Critical effect of peptide cyclization on the potency of peptide inhibitors against Dengue virus NS2B-NS3 protease.
Xu S; Li H; Shao X; Fan C; Ericksen B; Liu J; Chi C; Wang C
J Med Chem; 2012 Aug; 55(15):6881-7. PubMed ID: 22780881
[TBL] [Abstract][Full Text] [Related]
19. Discovery and design of cyclic peptides as dengue virus inhibitors through structure-based molecular docking.
Idrees S; Ashfaq UA
Asian Pac J Trop Med; 2014 Jul; 7(7):513-6. PubMed ID: 25063278
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain.
Shannon AE; Chappell KJ; Stoermer MJ; Chow SY; Kok WM; Fairlie DP; Young PR
Protein Expr Purif; 2016 Mar; 119():124-9. PubMed ID: 26647367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
